Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Review Article

Enhancing Therapeutic Efficacy of Donepezil by Combined Therapy: A Comprehensive Review

Author(s): Xi Rong, Liwei Jiang*, Meijie Qu , Syed Shams ul Hassan and Zongchao Liu

Volume 27, Issue 3, 2021

Published on: 23 October, 2020

Page: [332 - 344] Pages: 13

DOI: 10.2174/1381612826666201023144836

Price: $65

Abstract

Combination therapy involving different therapeutic strategies mostly provides more rapid and effective results as compared to monotherapy in diverse areas of clinical practice. The most worldwide famous acetylcholinesterase inhibitor (AChEIs) donepezil for its dominant role in Alzheimer’s disease (AD) has also attracted the attention of many pharmaceuticals due to its promising pharmacological potencies such as neuroprotective, muscle relaxant, and sleep inducer. Recently, a combination of donepezil with other agents has displayed better desirable results in managing several disorders, including the most common Alzheimer’s disease (AD). This study involves all the data regarding the therapeutic effect of donepezil in its combination with other agents and explains its therapeutic targets and mode of action. Furthermore, this review also puts light on the current status of donepezil with other agents in clinical trials. The combination therapy of donepezil with symptomatic relief drugs and disease-modifying agents opens a new road for treating multiple pathological disorders. To the best of our knowledge, this is the first report encircling all the pharmacologic effects of donepezil in its combination therapy with other agents and their current status in clinical trials.

Keywords: Donepezil, acetylcholinesterase inhibitor, combination therapy, Alzheimer's disease, mode of action, clinical trials, pharmaceuticals.

[1]
Yabuki Y, Matsuo K, Hirano K, Shinoda Y, Moriguchi S, Fukunaga K. Combined memantine and donepezil treatment improves behavioral and psychological symptoms of dementia-like behaviors in olfactory bulbectomized mice. Pharmacology 2017; 99(3-4): 160-71.
[http://dx.doi.org/10.1159/000452839] [PMID: 28049192]
[2]
Akinyemi AJ, Oboh G, Oyeleye SI, Ogunsuyi O. Anti-amnestic effect of curcumin in combination with donepezil, an anticholinesterase drug: Involvement of cholinergic system. Neurotox Res 2017; 31(4): 560-9.
[http://dx.doi.org/10.1007/s12640-017-9701-5] [PMID: 28102474]
[3]
Chen R, Chan PT, Chu H, et al. Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: A meta-analysis. PLoS One 2017; 12(8)e0183586
[http://dx.doi.org/10.1371/journal.pone.0183586] [PMID: 28827830]
[4]
Maidment ID, Fox CG, Boustani M, et al. Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis. Ann Pharmacother 2008; 42(1): 32-8.
[http://dx.doi.org/10.1345/aph.1K372]
[5]
Mintzer JE, Kershaw P. The efficacy of galantamine in the treatment of Alzheimer’s disease: comparison of patients previously treated with acetylcholinesterase inhibitors to patients with no prior exposure. Int J Geriatr Psychiatry 2003; 18(4): 292-7.
[http://dx.doi.org/10.1002/gps.826] [PMID: 12673604]
[6]
Casey DA, Antimisiaris D, O’Brien J. Drugs for Alzheimer’s disease: are they effective? P&T 2010; 35(4): 208-11.
[PMID: 20498822]
[7]
Sharma S, Taliyan R. Synergistic effects of GSK-3β and HDAC inhibitors in intracerebroventricular streptozotocin-induced cognitive deficits in rats. Naunyn Schmiedebergs Arch Pharmacol 2015; 388(3): 337-49.
[http://dx.doi.org/10.1007/s00210-014-1081-2] [PMID: 25547373]
[8]
Williams IM, Wallom KL, Smith DA, Al Eisa N, Smith C, Platt FM. Improved neuroprotection using miglustat, curcumin and ibuprofen as a triple combination therapy in Niemann-Pick disease type C1 mice. Neurobiol Dis 2014; 67: 9-17.
[http://dx.doi.org/10.1016/j.nbd.2014.03.001] [PMID: 24631719]
[9]
Batarseh YS, Kaddoumi A. Oleocanthal-rich extra-virgin olive oil enhances donepezil effect by reducing amyloid-β load and related toxicity in a mouse model of Alzheimer’s disease. J Nutr Biochem 2018; 55: 113-23.
[http://dx.doi.org/10.1016/j.jnutbio.2017.12.006] [PMID: 29413486]
[10]
Meng J, Li Y, Camarillo C, et al. The anti-tumor histone deacetylase inhibitor SAHA and the natural flavonoid curcumin exhibit synergistic neuroprotection against amyloid-beta toxicity. PLoS One 2014; 9(1)e85570
[http://dx.doi.org/10.1371/journal.pone.0085570] [PMID: 24409332]
[11]
Skovgard K, Agerskov C, Kohlmeier KA, Herrik KF. The 5-HT3 receptor antagonist ondansetron potentiates the effects of the acetylcholinesterase inhibitor donepezil on neuronal network oscillations in the rat dorsal hippocampus. Neuropharmacology 2018; 143: 130-42.
[http://dx.doi.org/10.1016/j.neuropharm.2018.09.017] [PMID: 30243914]
[12]
Amat-Foraster M, Leiser SC, Herrik KF, et al. The 5-HT6 receptor antagonist idalopirdine potentiates the effects of donepezil on gamma oscillations in the frontal cortex of anesthetized and awake rats without affecting sleep-wake architecture. Neuropharmacology 2017; 113(Pt A): 45-59.
[http://dx.doi.org/10.1016/j.neuropharm.2016.09.017] [PMID: 27647493]
[13]
Zaky A, Mahmoud M, Awad D, El Sabaa BM, Kandeel KM, Bassiouny AR. Valproic acid potentiates curcumin-mediated neuroprotection in lipopolysaccharide induced rats. Front Cell Neurosci 2014; 8: 337.
[http://dx.doi.org/10.3389/fncel.2014.00337] [PMID: 25374508]
[14]
Xie YG, Zhao XC, Hassan SS, et al. One new sesquiterpene and one new iridoid derivative from Valeriana amurensis. Phytochem Lett 2019; 32: 6-9.
[http://dx.doi.org/10.1016/j.phytol.2019.04.020]
[15]
Bretin S, Krazem A, Henkous N, et al. Synergistic enhancing-memory effect of donepezil and S 47445, an AMPA positive allosteric modulator, in middle-aged and aged mice. Psychopharmacology (Berl) 2018; 235(3): 771-87.
[http://dx.doi.org/10.1007/s00213-017-4792-5] [PMID: 29167913]
[16]
Feldman H, Gauthier S, Hecker J, et al. Efficacy and safety of donepezil in patients with more severe Alzheimer’s disease: a subgroup analysis from a randomized, placebo-controlled trial. Int J Geriatr Psychiatry 2005.
[http://dx.doi.org/10.1002/gps.1325]
[17]
Atri A, Molinuevo JL, Lemming O, Wirth Y, Pulte I, Wilkinson D. Memantine in patients with Alzheimer’s disease receiving donepezil: new analyses of efficacy and safety for combination therapy. Alzheimers Res Ther 2013; 5(1): 6.
[http://dx.doi.org/10.1186/alzrt160] [PMID: 23336974]
[18]
Robbins TW, Murphy ER. Behavioural pharmacology: 40+ years of progress, with a focus on glutamate receptors and cognition. Trends Pharmacol Sci 2006; 27(3): 141-8.
[http://dx.doi.org/10.1016/j.tips.2006.01.009] [PMID: 16490260]
[19]
Pirotte B, Francotte P, Goffin E, de Tullio P. AMPA receptor positive allosteric modulators: a patent review. Expert Opin Ther Pat 2013; 23(5): 615-28.
[http://dx.doi.org/10.1517/13543776.2013.770840] [PMID: 23405869]
[20]
Boada-Rovira M, Brodaty H, Cras P, et al. 322 Study Group. Efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a global, multinational, clinical experience study. Drugs Aging 2004; 21(1): 43-53.
[http://dx.doi.org/10.2165/00002512-200421010-00004] [PMID: 14715043]
[21]
Callahan PM, Hutchings EJ, Kille NJ, Chapman JM, Terry AV Jr. Positive allosteric modulator of αnicotinic-acetylcholine receptors, PNU-120596 augments the effects of donepezil on learning and memory in aged rodents and non-human primates. Neuropharmacology 2013; 67: 201-12.
[http://dx.doi.org/10.1016/j.neuropharm.2012.10.019] [PMID: 23168113]
[22]
Alzarea S, Rahman S. Effects of alpha-7 nicotinic allosteric modulator PNU 120596 on depressive-like behavior after lipopolysaccharide administration in mice. Prog Neuropsychopharmacol Biol Psychiatry 2018; 86: 218-28.
[http://dx.doi.org/10.1016/j.pnpbp.2018.05.018] [PMID: 29800595]
[23]
Wang J, Lindstrom J. Orthosteric and allosteric potentiation of heteromeric neuronal nicotinic acetylcholine receptors. Br J Pharmacol 2018; 175(11): 1805-21.
[http://dx.doi.org/10.1111/bph.13745] [PMID: 28199738]
[24]
Chase TN, Clarence-Smith K. High dose cholinesterase inhibitor treatment of Alzheimer’s disease AAIC Abstract 2015.
[http://dx.doi.org/10.1016/j.jalz.2015.06.491]
[25]
Chase TN, Farlow MR, Clarence-Smith K. Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer’s Disease. Neurotherapeutics 2017; 14(2): 405-16.
[http://dx.doi.org/10.1007/s13311-016-0511-x] [PMID: 28138837]
[26]
Leiser SC, Li Y, Pehrson AL, Dale E, Smagin G, Sanchez C. Serotonergic regulation of prefrontal cortical circuitries involved in cognitive processing: a review of individual 5-HT receptor mechanisms and concerted effects of 5-HT receptors exemplified by the multimodal antidepressant vortioxetine. ACS Chem Neurosci 2015; 6(7): 970-86.
[http://dx.doi.org/10.1021/cn500340j] [PMID: 25746856]
[27]
Draguhn A, Keller M, Reichinnek S. Coordinated network activity in the hippocampus. Front Neurol Neurosci 2014; 34: 26-35.
[http://dx.doi.org/10.1159/000357026] [PMID: 24777128]
[28]
Nyhus E, Curran T. Functional role of gamma and theta oscillations in episodic memory. Neurosci Biobehav Rev 2010; 34(7): 1023-35.
[http://dx.doi.org/10.1016/j.neubiorev.2009.12.014] [PMID: 20060015]
[29]
Ahnaou A, Huysmans H, Jacobs T, Drinkenburg WH. Cortical EEG oscillations and network connectivity as efficacy indices for assessing drugs with cognition enhancing potential. Neuropharmacology 2014; 86: 362-77.
[http://dx.doi.org/10.1016/j.neuropharm.2014.08.015] [PMID: 25181033]
[30]
Tort AB, Komorowski RW, Manns JR, Kopell NJ, Eichenbaum H. Theta-gamma coupling increases during the learning of item-context associations. Proc Natl Acad Sci USA 2009; 106(49): 20942-7.
[http://dx.doi.org/10.1073/pnas.0911331106] [PMID: 19934062]
[31]
Babiloni C, Del Percio C, Bordet R, et al. Effects of acetylcholinesterase inhibitors and memantine on resting-state electroencephalographic rhythms in Alzheimer’s disease patients. Clin Neurophysiol 2013; 124(5): 837-50.
[http://dx.doi.org/10.1016/j.clinph.2012.09.017] [PMID: 23098644]
[32]
Herrik KF. MA,rk A, Richard N, Bundgaard C, Bastlund JF, de Jong IEM. The 5-HT6 receptor antagonist idalopirdine potentiates the effects of acetylcholinesterase inhibition on neuronal network oscillations and extracellular acetylcholine levels in the rat dorsal hippocampus. Neuropharmacology 2016; 107: 351-63.
[http://dx.doi.org/10.1016/j.neuropharm.2016.03.043] [PMID: 27039041]
[33]
Sotty F, Danik M, Manseau F, Laplante F, Quirion R, Williams S. Distinct electrophysiological properties of glutamatergic, cholinergic and GABAergic rat septohippocampal neurons: novel implications for hippocampal rhythmicity. J Physiol 2003; 551(Pt 3): 927-43.
[http://dx.doi.org/10.1113/jphysiol.2003.046847] [PMID: 12865506]
[34]
Cachard-Chastel M, Devers S, Sicsic S, et al. Prucalopride and donepezil act synergistically to reverse scopolamine-induced memory deficit in C57Bl/6j mice. Behav Brain Res 2008; 187(2): 455-61.
[http://dx.doi.org/10.1016/j.bbr.2007.10.008] [PMID: 18061284]
[35]
Freret T, Bouet V, Quiedeville A, et al. Synergistic effect of acetylcholinesterase inhibition (donepezil) and 5-HT(4) receptor activation (RS67333) on object recognition in mice. Behav Brain Res 2012; 230(1): 304-8.
[http://dx.doi.org/10.1016/j.bbr.2012.02.012] [PMID: 22348892]
[36]
Ferris CF, Kulkarni P, Yee JR, Nedelman M, de Jong IEM. The Serotonin receptor 6 antagonist idalopirdine and acetylcholinesterase inhibitor donepezil have synergistic effects on brain activity-a functional MRI study in the awake rat. Front Pharmacol 2017; 8: 279.
[http://dx.doi.org/10.3389/fphar.2017.00279] [PMID: 28659792]
[37]
Molinuevo JL, Ramaswamy S, Lombardo I, et al. Responder analysis of the cognitive effect of combination therapy with donepezil and intepirdine (RVT-101) versus donepezil monotherapy: results from a 48-week multinational placebo-controlled study in mild to moderate Alzheimer’s disease. Alzheimers Dement 2017; 13(7): 259.
[http://dx.doi.org/10.1016/j.jalz.2017.06.125]
[38]
Nirogi R, Shinde A, Kambhampati RS, et al. Discovery and development of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate (SUVN-502): A novel, potent, selective and orally active serotonin 6 (5-HT6) receptor antagonist for potential treatment of alzheimer’s disease. J Med Chem 2017; 60(5): 1843-59.
[http://dx.doi.org/10.1021/acs.jmedchem.6b01662] [PMID: 28212021]
[39]
Jayarajan P, Abraham R, Bhyrapuneni G, et al. 5-ht6 antagonist SUVN-502 potentiates the procognitive and neurochemical effects of donepezil and memantine. Alzheimers Dement 2015; 11(7): 472.
[http://dx.doi.org/10.1016/j.jalz.2015.06.517]
[40]
Markesbery WR. Oxidative stress hypothesis in Alzheimer’s disease. Free Radic Biol Med 1997; 23(1): 134-47.
[http://dx.doi.org/10.1016/S0891-5849(96)00629-6] [PMID: 9165306]
[41]
Hassan SS, Anjum K, Abbas SQ, et al. Emerging biopharmaceuticals from marine actinobacteria. Environ Toxicol Pharmacol 2017; 49: 34-47.
[http://dx.doi.org/10.1016/j.etap.2016.11.015] [PMID: 27898308]
[42]
Pappolla MA, Chyan YJ, Omar RA, et al. Evidence of oxidative stress and in vivo neurotoxicity of β-amyloid in a transgenic mouse model of Alzheimer’s disease: a chronic oxidative paradigm for testing antioxidant therapies in vivo. Am J Pathol 1998; 152(4): 871-7.
[PMID: 9546346]
[43]
Agunloye OM, Oboh G. Modulatory effect of caffeic acid on cholinesterases inhibitory properties of donepezil. J Complement Integr Med 2017; 15(1): 16.
[44]
Castagna A, Ruberto C, Ruotolo G. Donepezil and vitamin D in alzheimer’s disease: the donde study. Alzheimers Dement 2016; 12(7): 1184-5.
[http://dx.doi.org/10.1016/j.jalz.2016.07.130]
[45]
Kim HY, Kim HV, Lee DK, Yang SH, Kim Y. Rapid and sustained cognitive recovery in APP/PS1 transgenic mice by co-administration of EPPS and donepezil. Sci Rep 2016; 6: 34165.
[http://dx.doi.org/10.1038/srep34165] [PMID: 27796293]
[46]
Xiao Y, Zhu S, Wu G, et al. Chemical Constituents of Vernonia parishii. Chem Nat Compd 2020; 56(1): 134-6.
[http://dx.doi.org/10.1007/s10600-020-02963-x]
[47]
Khan I, Abbas T, Anjum K, et al. Antimicrobial potential of aqueous extract of Camellia sinensis against representative microbes. Pak J Pharm Sci 2019; 32(2): 631-6.
[PMID: 31081776]
[48]
Shams Ul Hassan S, Jin HZ, Abu-Izneid T, Rauf A, Ishaq M, Suleria HAR. Stress-driven discovery in the natural products: A gateway towards new drugs. Biomed Pharmacother 2019; 109: 459-67.
[http://dx.doi.org/10.1016/j.biopha.2018.10.173] [PMID: 30399582]
[49]
Gu C, Shen T, An H, et al. Combined therapy of Di-Huang-Yi-Zhi with Donepezil in patients with Parkinson’s disease dementia. Neurosci Lett 2015; 606: 13-7.
[http://dx.doi.org/10.1016/j.neulet.2015.08.019] [PMID: 26297124]
[50]
Stein C, Hopfeld J, Lau H, Klein J. Effects of Ginkgo biloba extract EGb 761, donepezil and their combination on central cholinergic function in aged rats. J Pharm Pharm Sci 2015; 18(4): 634-46.
[http://dx.doi.org/10.18433/J3WC8V] [PMID: 26626253]
[51]
Zhang J, Wang J, Zhou G-S, et al. Studies of the anti-amnesic effects and mechanisms of single and combined use of donepezil and ginkgo ketoester tablet on scopolamine-induced memory impairment in mice. Oxid Med Cell Longev 2019; 20198636835
[http://dx.doi.org/10.1155/2019/8636835] [PMID: 30911351]
[52]
Maruyama M, Tomita N, Iwasaki K, et al. Benefits of combining donepezil plus traditional Japanese herbal medicine on cognition and brain perfusion in Alzheimer’s disease: a 12-week observer-blind, donepezil monotherapy controlled trial. J Am Geriatr Soc 2006; 54(5): 869-71.
[http://dx.doi.org/10.1111/j.1532-5415.2006.00722.x] [PMID: 16696770]
[53]
Jia Y, Zhang X, Yu J, et al. Acupuncture for patients with mild to moderate Alzheimer’s disease: a randomized controlled trial. BMC Complement Altern Med 2017; 17(1): 556.
[http://dx.doi.org/10.1186/s12906-017-2064-x] [PMID: 29284465]
[54]
Liu Q, Wang XJ, Zhang ZC, Xue R, Li P, Li B. Neuroprotection against vascular dementia after acupuncture combined with donepezil hydrochloride: P300 event related potential. Neural Regen Res 2016; 11(3): 460-4.
[http://dx.doi.org/10.4103/1673-5374.179059] [PMID: 27127486]
[55]
Yan W, Qin WG, Yu CD. Clinical observation on effect of cranial suture acupuncture combined with donepezil hydrochloride tablets for Alzheimer’s disease. Wor J Acupunc Moxi 2014; 24: 19-24.
[http://dx.doi.org/10.1016/S1003-5257(14)60020-9]
[56]
Hashimoto T, Hatayama Y, Nakamichi K, Yoshida N. Procognitive effect of AC-3933 in aged mice, and synergistic effect of combination with donepezil in scopolamine-treated mice. Eur J Pharmacol 2014; 745: 123-8.
[http://dx.doi.org/10.1016/j.ejphar.2014.10.015] [PMID: 25446931]
[57]
Sors A, Krazem A, Kehr J, et al. The synergistic enhancing-memory effect of donepezil and S 38093 (a Histamine H3 Antagonist) is mediated by increased neural activity in the septo-hippocampal circuitry in middle-aged mice. Front Pharmacol 2016; 7: 492.
[http://dx.doi.org/10.3389/fphar.2016.00492] [PMID: 28066242]
[58]
de Bruin NM, Prickaerts J, Lange JHM, et al. SLV330, a cannabinoid CB1 receptor antagonist, ameliorates deficits in the T-maze, object recognition and Social Recognition Tasks in rodents. Neurobiol Learn Mem 2010; 93(4): 522-31.
[http://dx.doi.org/10.1016/j.nlm.2010.01.010] [PMID: 20132903]
[59]
Eskandary A, Moazedi AA, Varzi NZ. Combined effects of donepezil and lovastatin on cognition deficit induced by bilateral lesion of the Nucl. Basalis Magnocellularis in a Rat Model of Alzheimer’s disease. Neurophysiology 2018; 50: 99-107.
[http://dx.doi.org/10.1007/s11062-018-9723-5]
[60]
Maurice T. Protection by sigma-1 receptor agonists is synergic with donepezil, but not with memantine, in a mouse model of amyloid-induced memory impairments. Behav Brain Res 2016; 296: 270-8.
[http://dx.doi.org/10.1016/j.bbr.2015.09.020] [PMID: 26386305]
[61]
Hassan SSU, Shaikh AL. Marine actinobacteria as a drug treasure house. Biomed Pharmacother 2017; 87: 46-57.
[http://dx.doi.org/10.1016/j.biopha.2016.12.086] [PMID: 28040597]
[62]
Anjum K, Abbas SQ, Akhter N, Shagufta BI, Shah SAA, Hassan SSU. Emerging biopharmaceuticals from bioactive peptides derived from marine organisms. Chem Biol Drug Des 2017; 90(1): 12-30.
[http://dx.doi.org/10.1111/cbdd.12925] [PMID: 28004491]
[63]
NCT00704782 An open-label extension study of combination therapy with dimebon and donepezil in patients with alzheimer's disease Available from: https://www.clinicaltrials.gov/ct2/show/NCT00704782
[64]
NCT02580305. A phase 2a multicenter, randomized, double-blind, parallel group, 26-week, placebo-controlled study of suvn-502 in subjects with moderate Alzheimer's disease currently treated with donepezil hydrochloride and memantine hydrochloride. https://www.clinicaltrials.gov/ct2/show/NCT02580305
[65]
NCT02585934 Double-blind, randomized study of RVT-101 versus placebo when added to existing stable donepezil treatment in subjects with mild to moderate Alzheimer’s disease Available from: https://www.clinicaltrials.gov/ct2/show/NCT02585934
[66]
NCT02006641 Randomised, double-blind, parallel-group, placebo-controlled, fixed-dose study of idalopirdine in patients with mild-moderate Alzheimer’s disease treated with Donepezil Available from: https://www.clinicaltrials.gov/ct2/show/NCT02006641
[67]
NCT02079246. An open-label extension study to evaluate the longterm safety and tolerability of idalopirdine (LU AE58054) as adjunctive treatment to donepezil in patients with mild-moderate Alzheimer's disease. https://www.clinicaltrials.gov/ct2/show/NCT02079246
[68]
NCT02185053 A phase II, single-blind, placebo-controlled, sequential treatment, multiple ascending dose study to evaluate the safety and tolerability of CPC-201 in patients With Alzheimer's Disease Type Dementia Available from: https://www.clinicaltrials.gov/ct2/show/NCT02185053
[69]
NCT02549196 A phase II, dose titration study of CPC-201 in patients with dementia of Alzheimer's type Available from: https://www.clinicaltrials.gov/ct2/show/study/NCT02549196
[70]
NCT00519298 A double-blind, placebo-controlled, balanced, 4- way, incomplete block design to evaluate the effects of a single administration of SAM-531 on Sleep Electroencephalogram (EEG) and Quantitative Wake EEG (qEEG) in healthy subjects.Available from: https://www.clinicaltrials.gov/ct2/show/NCT00519298
[71]
NCT03090516 Clinical study on improving the cognitive function of patients with mild to moderate Alzheimer’s disease by using ginkgo biloba dispersible tablets Available from: https://www.clinicaltrials.gov/ct2/show/NCT03090516
[72]
NCT03810794 Clinical evaluation on the therapeutic effect of acupuncture treatment for Alzheimer’s disease: multicenter randomized controlled trial Available from: https://www.clinicaltrials.gov/ct2/show/NCT03810794
[73]
NCT03055741. A Multicenter, randomized, double-blind, placebocontrolled, phase iib, clinical study to evaluate the safety and efficacy of DHP1401 in patients with mild-moderate Alzheimer’s disease treated with donepezil (DRAMA). Available from: https://www.clinicaltrials.gov/ct2/show/NCT03055741

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy